Metabolic Syndrome and Asthma

ISSN: 2212-3334 (Online)
ISSN: 1872-2148 (Print)

Volume 11, 2 Issues, 2017

Download PDF Flyer

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Metabolic Syndrome and Asthma

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 8(1): 60-66.

Author(s): Jenny V. Garmendia, Dolores Moreno, Alexis H. Garcia and Juan B De Sanctis.

Affiliation: Instituto de Inmunologia, Facultad de Medicina, Universidad Central de Venezuela, Apartado 50109, Caracas 1050-A, Venezuela.


Metabolic syndrome (MetS) is a syndrome that involves at least three disorders dyslipidemia, insulin resistance, obesity and/or hypertension. MetS has been associated with several chronic diseases in the adulthood; however, in the recent years, the syndrome was redefined in children. Girls with early menarche and asthma, and children with MetS and asthma that reach adulthood appear to have higher risk to develop severe or difficult to control asthma and a higher probability to suffer cardiovascular diseases. It has been proposed that patients with MetS and endocrinological disorders should be considered a different entity in which pharmacologic treatment should be adjusted according to the individual. Recent patents on the field have addressed new issues on how endocrine control should be managed along with asthma therapeutics. In the near future, new approaches should decrease the high morbidity and mortality associated to these types of patients.


Asthma, dyslipidemia, hypertension, immune response, insulin resistance, metabolic syndrome.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 1
First Page: 60
Last Page: 66
Page Count: 7
DOI: 10.2174/1872214807666140107151023

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science